Compare Smith & Nephew plc (SNN) vs Global X Uranium ETF (URA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Smith & Nephew plc vs Global X Uranium ETF — how do they compare? Smith & Nephew plc trades at $27.67 (market cap $11.63B), while Global X Uranium ETF trades at $46.75. The key difference: Smith & Nephew plc pays a 2.85% dividend while Global X Uranium ETF pays none, and Global X Uranium ETF is trading nearer its 52-week high, Smith & Nephew plc nearer its low. Which is the better fit depends on your goals.
| SNN | URA | |
|---|---|---|
Market Cap | $11.63B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $38.53 | $61.81 |
52-Week Low | $27.80 | $37.52 |
Enterprise Value | $14.66B | — |
Dividend Yield | 2.85% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Smith & Nephew (SNN) trades at $27.87, down 3.46% over 24 hours and near its 52-week low. The stock shows a bearish technical trend with mixed sentiment; recent earnings have mostly beaten expectations, but Q2 2026 revenue growth missed and guidance was cut. Fundamentals are solid with revenue rising to $6.16B in 2025 and net income margin improving to 10.08%, though debt levels have increased. The company faces competitive pressures in key markets like U.S. Orthopaedics.
Outlook is cautious: valuation ratios like P/E of 18.96 are reasonable, but analyst consensus is Hold (65%) due to execution risks and CFO departure. Opportunities include innovation in surgical robotics and new product launches, but investors should monitor U.S. market weakness and debt management for sustained recovery.
URA (Global X Uranium ETF) trades at $47.50, up 3.13% today, with strong bullish technical signals from moving averages. The ETF benefits from growing nuclear energy demand driven by AI power needs and government support, including recent $17.5 billion in U.S. reactor funding. However, key financial ratios remain unavailable, and the sector faces volatility from uranium price fluctuations and regulatory shifts.
Outlook remains positive due to structural tailwinds in nuclear energy, but investors should monitor uranium contract pricing and ETF expense ratios. Near-term resistance sits at $48-$50, with support at $45-$47. Risks include policy changes and miner concentration, though institutional interest in nuclear ETFs is rising.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →About Global X Uranium ETF
URA provides broad exposure to the global uranium industry and nuclear energy sector. Unlike pure-play mining funds, it includes companies involved in nuclear component production and infrastructure, with top 2026 holdings such as Cameco, Oklo, and Uranium Energy Corp.
Read more on URA →
